Fosun Pharma`s MSCI ESG rating jumps to A

Recently, the international authoritative index agency Morgan Stanley Capital International (“Mingsheng” in Chinese, “MSCI” in English) announced the latest annual Environmental, Social and Governance (“ESG”) rating results. With its outstanding performance in ESG, Fosun Pharma (stock code: 600196.SH, 02196.HK) MSCI ESG jumped to Grade A, leading the domestic industry. Fosun Pharma’s MSCI ESG rating has been upgraded from BB in 2020 to BBB in 2021. This time, MSCI has raised the rating to A again, which shows the high recognition of Fosun Pharma’s ESG management by the capital market, and it is more important for the company’s long-term investment value. affim.